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Abstract
Apathy is a reduction in goal-directed activity in the cognitive, behavioral, emotional, or social domains of a patient’s life
and occurs in one out of three patients after stroke. Despite this, apathy is clinically under-recognized and poorly
understood. This overview provides a contemporary introduction to apathy in stroke for researchers and practitioners,
covering topics including diagnosis, neurobiological mechanisms, associated consequences, and potential treatments for
apathy. Apathy is often misdiagnosed as other post-stroke conditions such as depression. Accurate differential diagnosis
of apathy, which manifests as reductions in initiative, and depression, which manifests as negative emotionality, is import-
ant as it informs prognosis. Research on the neurobiology of apathy suggests that there are few consistent associations
between stroke lesion location and the development of apathy. These may be resolved by adopting a network neuro-
science approach, which models apathy as a pathology arising from structural or functional damage to brain networks
underlying motivated behavior. Importantly, networks can be affected by physiological changes related to stroke, includ-
ing the acute infarct but also diaschisis and neurodegeneration. Aside from neurobiological changes, apathy is also
associated with other negative outcome measures such as functional disability, cognitive impairment, and emotional
distress, suggesting that apathy is indicative of a worse prognosis following stroke. Unfortunately, high-quality trials aimed
at treating apathy are scarce. Antidepressants may have limited effects on apathy. Acetylcholine and dopamine pharma-
cotherapy, behavioral interventions, and transcranial magnetic stimulation may be more promising avenues for treatment.
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Introduction
Apathy is a behavioral syndrome characterized by a
loss of motivation that occurs in one-third of patients
after stroke.1,2 Post-stroke patients with apathy suffer
from greater functional impairment and demonstrate
slower recovery times to normal functioning.3,4
Furthermore, apathy is a risk factor for incident vascu-
lar disease, dementia, and mortality.5,6 Despite high
prevalence and an impact on outcomes after stroke,
apathy remains poorly understood. It is also under-
recognized, although the extent of this is unknown.
This leads to a dearth of treatment approaches. This
overview provides a contemporary introduction to
apathy in stroke for researchers and practitioners, cov-
ering topics including diagnosis, neurobiological mech-
anisms, associated consequences, and potential
treatments for apathy. The search strategy and selec-
tion criteria for papers referenced in this overview can
be found after the ‘‘Discussion’’ section.
Diagnostic criteria for apathy
Apathy can be defined as a quantitative reduction in
goal-directed behaviors (GDB) occurring in the cogni-
tive/behavioral, emotional, or social domains of an
individual’s life (Box 1).7 Reductions are relative to
an individual’s previous level of functioning and can
be reported by the individual or others. A previous ver-
sion of these diagnostic guidelines has been validated in
patients with a range of neurological disorders, includ-
ing those with cerebrovascular damage, showing good
inter-rater reliability.8
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Box 1. Diagnostic criteria for apathy.
CRITERION A: A quantitative reduction of goal-directed activity either in behavioral, cognitive, emotional or social dimensions
in comparison to the patient’s previous level of functioning in these areas. These changes may be reported by the patient them-
selves or by observation of others.
CRITERION B: The presence of at least two of the three following dimensions for a period of at least four weeks and present
most of the time:
B1. BEHAVIOR AND COGNITION
Loss of, or diminished, goal-directed behavior or cognitive activity as evidenced by at least one of the following:
General level of activity: The patient has a reduced level of activity either at home or work, makes less effort to initiate or accomplish
tasks spontaneously or needs to be prompted to perform them.
Persistence of activity: They are less persistent in maintaining an activity or conversation, finding solutions to problems or thinking of
alternative ways to accomplish them if they become difficult.
Making choices: They have less interest or take longer to make choices when different alternatives exist.
Interest in external issue: They have less interest in or reacts less to news, either good or bad, or has less interest in doing new
things.
Personal wellbeing: They are less interested in their own health and wellbeing or personal image.
B2. EMOTION
Loss of, or diminished, emotion as evidenced by at least one of the following:
Spontaneous emotions: The patient shows less spontaneous (self-generated) emotions regarding their own affairs or appears less
interested in events that should matter to them or to people that they know well.
Emotional reactions to environment: They express less emotional reaction in response to positive or negative events in their envir-
onment that affect them or people they know well.
Impact on others: They are less concerned about the impact of their actions or feelings on the people around them.
Empathy: They show less empathy to the emotions or feelings of others.
Verbal or physical expressions: They show less verbal or physical reactions that reveal their emotional states.
B3. SOCIAL INTERACTION
Loss of or diminished engagement in social interaction as evidenced by at least one of the following:
Spontaneous social initiative: The patient takes less initiative in spontaneously proposing social or leisure activities to family or others.
Environmentally stimulated social interaction: They participate less or are less comfortable or more indifferent to social or leisure
activities suggested by people around them.
Relationship with family members: They show less interest in family members.
Verbal interaction: They are less likely to initiate a conversation or withdraw soon from it.
Homebound: They prefer to stay at home more frequently or longer than usual and show less interest in getting out to meet people.
CRITERION C: These symptoms (A–B) cause clinically significant impairment in personal, social, occupational, or other import-
ant areas of functioning.
CRITERION D: The symptoms (A–B) are not exclusively explained or due to physical disabilities, to motor disabilities, to a
diminished level of consciousness, to the direct physiological effects of a substance, or to major changes in the patient’s
environment.
Adapted with permission.7
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Apathy can be suspected in routine clinical practice
during the history taking and examination from an
observed loss of motivation. Informant histories may
also reveal symptoms of apathy, such as loss of interest
in previous activities and hobbies or doing little when
left alone, which can be valuable as patients may under-
play symptoms. Apathy assessments can be supple-
mented with semi-structured interviews or
questionnaires (Table 1, Supplementary Table 1).
These are less thorough than clinical examinations
but can be administered more flexibly, which can be
useful for research and screening.
Apathy is described as a symptom in the International
Classification of Diseases, Eleventh Revision under code
MB24.4. Similarly, the Diagnostic and Statistical Manual
of Mental Disorders, Fifth Edition acknowledges apathy
as a symptom of other disorders, such as mood and
neurocognitive disorders.9 Unfortunately, neither classi-
fication system describes apathy as a syndrome, poten-
tially limiting its recognition.
Differential diagnosis of post-stroke
apathy
Diagnosing apathy may be complicated by other post-
stroke neuropsychiatric symptoms, particularly depres-
sion. Core symptoms of a depressive episode, which can
be triggered by stroke, include low mood and dimin-
ished pleasure (anhedonia).9 Depressive symptoms such
as anhedonia can appear behaviorally similar to apathy
and may have a similar neurobiological basis, making
them difficult to distinguish in practice (Figure 1(a)).
Despite shared symptoms, post-stroke apathy and
depression are dissociable syndromes with different
prevalence rates (Figure 1(b)). Stroke patients tend to
develop either apathy or depression, with a minority
showing symptoms of both (Figure 1(b)).
Furthermore, apathy and depression have different tra-
jectories10,11 and effects on outcomes such as functional
disability12,13 and cognition.6,14,15
Negative emotionality is a key characteristic of
depression that distinguishes it from apathy.
Depressed patients may present with pessimism and
hopelessness, while those with apathy show a lack of
emotional distress.16 Depressed patients can also
actively engage in avoidant behavior, resisting socializ-
ing and treatment attempts, while apathetic patients are
passive and indifferent to these activities.16
Post-stroke fatigue may also be a potential com-
orbidity with post-stroke apathy. Fatigue can be
defined as a subjective feeling of extreme and persistent
physical/mental tiredness, weakness, or exhaustion.17
Although fatigue has a similar behavioral mani-
festation to apathy (i.e. less energy), preliminary
findings indicate that they are not correlated and
do not interact,18 suggesting that the two are
independent.
Apathy itself may present differently based on the
underlying neurological disease. More patients with
mixed dementia, which includes individuals with cere-
brovascular disease, may show deficits in behavioral
initiation compared to patients with other neurocogni-
tive diseases.8 Conversely, mixed dementia patients also
show the lowest proportion of emotional impairment
compared to other disorders except major depression.8
Although these patients did not have stroke per se,
stroke pathology is highly prevalent in mixed
dementia.19
Table 1. Commonly used apathy scales.
Scale Administration Questions Subscales
Apathy Evaluation Scale Self-report, Informant-rated, Clinician-
rated
18 Behavior, Cognition, Emotion, Other
Apathy Inventory Rated based on informant or patient
interview
3 Lack of Initiative, Lack of Interest,
Emotional Blunting
Apathy-Motivation Index Self-report 18 Behavioral, Social, Emotional
Dimensional Apathy Scale Self-report, Informant-rated 24 Behavioral/Cognitive Initiation, Executive,
Emotional
Lille Apathy Rating Scale Clinician-rated based on patient self-
report
33 Action Initiation, Self-awareness,
Intellectual Curiosity, Emotion
Starkstein Apathy Scale Examiner reads questions and
responses to patient
14 None
Some scales have not been validated in stroke patients; see references in Supplementary Table 1.
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Prevalence and natural history of
post-stroke apathy
Apathy presents in approximately one-third of
stroke patients, with symptoms beginning as early as
four days post-stroke.20 Longitudinal research suggests
that most post-stroke patients have a constant level of
high (7%), moderate (33%), or low/no (50%) apathy
for up to a year after stroke, with a minority improving
(7%) or worsening (7%).4 The prevalence of apathy
increases by 10% five years following stroke,21
although this may be an underestimate as patients




Post-stroke apathy is increasingly recognized as a con-
sequence of neurobiological changes triggered by a
stroke. Apathy is traditionally described as the result
of damage to specific brain structures related to GDB
such as the basal ganglia and prefrontal cortex.22 If this
lesion-deficit view of apathy was true, one would expect
Figure 1. Apathy and depression are dissociable syndromes: (a) distinct and overlapping symptoms of apathy and depression.
Apathy manifests as a reduction in goal-directed behaviors while depression is marked by negative emotionality. Overlapping
symptoms include loss of pleasure and energy; (b) prevalence rates of post-stroke apathy and depression in studies with n 100.
Patients present with either apathy or depression, with a minority showing comorbid symptoms. Distinguishing between the two
informs prognosis and treatment.
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a clear relationship between lesion location and apathy.
However, no common localizations across stroke stu-
dies have been found,2,23 suggesting that relationships
between structural damage and functional deficits are
more complex than initially thought.
A recent theoretical approach has recontextualized
apathy in cerebrovascular disease as the product of
damage to brain networks underlying GDB.24 This net-
work-based framework suggests that post-stroke apathy
follows focal lesions in key network regions or diffuse
cerebrovascular pathology disrupting connections
within networks. Acute infarcts to core brain regions
underlying GDB can result in apathy, recapitulating the
lesion-deficit view. Alternatively, diffuse white matter
damage due to cerebral small vessel disease can lead to
network disruption,25 explaining associations between
MRI markers of small vessel disease and apathy.26
This framework also suggests that post-stroke phe-
nomena such as functional diaschisis and secondary
neurodegeneration drive increases in apathy over
time.27 These phenomena can occur distal to an acute
infarct, leading to clinical symptoms that appear incon-
sistent or unexpected if only considering a focal lesion.
Importantly, secondary neurobiological changes can
propagate through structural and functional connec-
tions within the brain, potentially leading to apathy if
affecting GDB-related networks (Figure 2). As a corol-
lary, apathy may improve in response to restorative
mechanisms such as adaptive plasticity and functional
remapping.27
The anterior cingulate cortex (ACC) and nucleus
accumbens may be core network regions supporting
GDB, as damage to these structures is associated with
apathy across neurological disorders.28 These core
regions are embedded in large-scale functionally con-
nected networks that underlie GDB-related cognitive
functions such as reward-based decision-making, atten-
tional control, and reinforcement learning.24,28
Disruption to these networks may lead to cognitive def-
icits that manifest behaviorally as apathy
(Supplementary Table 2).24
This network-based conceptualization of apathy
explains a wide range of findings in patients with
post-stroke apathy, although further testing of it is
necessary. Future work could investigate time since
stroke in conjunction with more precise localizations
of the acute infarct and any white matter ischemia,
given the specificity of the neuroanatomical networks
and neurophysiological processes that may be related
to post-stroke apathy.24
Effects of apathy on functional
outcomes
Post-stroke apathy is associated with functional disabil-
ity, including reductions in basic activities of daily
living such as eating or dressing and slower functional
recovery over time.2,3,12 Factors underlying these rela-
tionships remain unexplored, although a potential
explanation is that motivational deficits impair recov-
ery by reducing engagement in rehabilitation programs.
Alternatively, apathy could precede sedentary behav-
ior, explaining associations between apathy and inci-
dent vascular disease.5
Figure 2. A network-based model of how stroke leads to apathy. Apathy can result from focal lesions disrupting key network
regions or from diffuse damage such as white matter ischemia. Acute strokes may not immediately lead to apathy symptoms if not
occurring in brain regions supporting goal-directed behaviors but can result in the delayed onset of apathy. Infarcts may lead to
disrupted functioning in connected areas, known as diaschisis. Over time, secondary neurodegenerative processes lead to atrophy
in regions structurally connected to the infarct, which propagates diaschisis-related deficits further throughout the brain. This
network-based spreading of stroke-related pathology may explain why apathy can occur in individuals who do not have acute
infarcts in motivation-related regions, and why apathy symptoms worsen in some patients over time.
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Apathy is associated with general cognitive deficits,
with post-stroke apathy patients scoring 2–3 points
lower on the Mini-Mental State Examination.2
Apathy has also been associated with impairments in
specific cognitive domains such as verbal learning,
short- and long-term verbal recall, semantic fluency,
abstract reasoning, and attention and concentra-
tion.11,14,15,29 This suggests that some post-stroke
patients with apathy suffer from cognitive impairment,
particularly in executive and memory-related domains,
supporting the notion that similar neurobiological net-
works underlie cognitive function and motivated
behavior.24,26 These cognitive deficits may have func-
tional consequences. Apathetic patients show dimin-
ished instrumental activities of daily living, which are
tasks that require planning such as shopping and
housekeeping.29,30 Furthermore, apathy is associated
with worse scores on dementia scales and a higher
risk of incident dementia, suggesting that apathy may
be symptomatic of prodromal vascular dementia.6,31
Finally, although apathy can co-occur with depression,
apathy may be a risk factor for developing subsequent
depression.10 Apathy is also associated with suicidal idea-
tion independently of depression three months after
stroke.32 This suggests that apathy can not only occur in
tandem with depression but also exacerbate it.
Treatments for post-stroke apathy
There is a lack of high-quality evidence to guide man-
agement of post-stroke apathy. Treatment can be con-
sidered under pharmacological, behavioral, and other
approaches. Given the importance of treatment, we
have included all trials that were found (Search strategy
and selection criteria).
Pharmacological approaches for treating apathy
Antidepressants such as selective serotonin reuptake
inhibitors (SSRIs) may be prescribed for apathy in clin-
ical practice due to shared symptomatology with
depression. Unfortunately, little evidence suggests that
antidepressants are effective for treating apathy in the
absence of additional depressive symptoms, with some
research suggesting that certain antidepressants exacer-
bate effort-based decision-making deficits.33
One double-blind placebo-controlled trial examined
the effects of the SSRI escitalopram (10mg/day in
patients 65 or 5mg/day in patients >65) in apathy-
free stroke patients.34 After 12 months, the 51 partici-
pants receiving escitalopram were 3.47 times less likely
to develop apathy compared to the 47 on placebo.34
This suggests that escitalopram reduces apathy risk,
though future trials are needed to determine whether
it ameliorates existing post-stroke apathy.
Two double-blind placebo-controlled trials have
evaluated the efficacy of nefiracetam, which enhances
monoaminergic, cholinergic, and GABAergic signaling
to treat post-stroke apathy. The first was conducted in
patients with post-stroke depression and apathy and
assigned patients to placebo (n¼ 22), 600mg/day nefir-
acetam (n¼ 26), or 900mg/day nefiracetam (n¼ 22).35
After 12 weeks, the patients receiving 900mg nefirace-
tam had a greater reduction in apathy compared to
those receiving 600mg nefiracetam or placebo. The
second study examined post-stroke apathy patients
and assigned participants 900mg/day nefiracetam
(n¼ 6) or placebo (n¼ 7), but did not find a statistically
significant decrease in apathy after 12 weeks.36 The
conflicting results of these studies should be interpreted
with caution due to small samples.
One open-label trial examined the acetylcholinester-
ase inhibitors galantamine and donepezil in treating
apathy in 26 cognitively impaired stroke patients.37
Thirteen patients were administered galantamine on a
dosing regimen starting at 4mg twice per day (b.i.d.)
before increasing to 8mg b.i.d. and then 12mg b.i.d. in
four-week increments. Remaining patients were admin-
istered donepezil starting at 5mg/day before increasing
to 10mg/day in six-week increments. After 12 weeks,
the entire sample showed a non-statistically significant
decrease in apathy compared to baseline.37
Acetylcholinesterase inhibitors warrant further consid-
eration, however, given the small sample in this study
and positive results in dementia studies.38
These inconclusive results preclude the recommenda-
tion of any pharmacological treatment for apathy in
stroke, although research in other neurological diseases
may provide avenues for future investigation. For
instance, acetylcholinesterase inhibitors show promise
in treating apathy in dementia,38 while dopamine has
been suggested as a treatment for apathy in Parkinson’s
disease given the role of this neurotransmitter in moti-
vated decision-making.39 Theoretical work predicts
that dopamine-based improvements in apathy are par-
alleled by increased reward sensitivity during behav-
ioral tasks and improved functional connectivity
within fronto-striatal networks.24
Behavioral approaches for treating apathy
Neuropsychological advice can be provided to patients
with apathy in the context of more general rehabilita-
tion procedures and can be delivered individually or in
formal group settings. Patients can be engaged in goal
setting with an emphasis on planning future goals and
evaluating success to help re-establish GDB.40
Complimentary approaches include problem-solving,
wherein a patient selects an activity and makes a plan
to achieve it while self-monitoring the process and
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outcome.34 Behavioral activation can be combined with
cognitive-behavioral therapy which explores psycho-
logical issues that may prevent GDB engagement.
Approaches should foster a sense of the self, belonging,
and respect and be tailored toward settings, where
patients can derive enjoyment from exercises and activ-
ities such as planned outings consistent with personal
backgrounds.41
Few trials have evaluated behavioral approaches for
treating apathy after stroke. One study on post-stroke
patients without apathy found that 56 patients
undergoing problem-solving therapy were 1.84 times
less likely to developing apathy compared to 47 patients
on placebo, though risk was even lower for patients
receiving escitalopram.34 A randomized trial examined
strategy training, wherein patients are coached to focus
on self-selected activity goals and encouraged to derive
strategies to address performance in pursuit of those
goals, to treat apathy in cognitively impaired stroke
patients.40 After three months, 15 patients undergoing
strategy training had significantly lower apathy com-
pared to 15 in a control condition.40 Group differences
were also found after six months, although these were
not statistically significant. Another randomized trial
examined the efficacy of a group-based approach to
promote activity for treating post-stroke symptoms
including apathy in 186 patients.41 Groups met in a
community-based setting twice a week for 3 h each,
during which they engaged in exercise, project-based
activities, and planned outings. Apathy decreased
over the course of the 12-month intervention compared
to baseline, although changes were not statistically sig-
nificant. Apathy was significantly lower after a 15-
month follow-up, however, suggesting that motivation
continued to improve after the intervention.
Other approaches for treating post-stroke apathy
Repetitive transcranial magnetic stimulation (rTMS)
has been used to treat post-stroke apathy. One rando-
mized sample of chronic stroke patients showed that
high-frequency rTMS over the ACC and medial pre-
frontal cortex improved apathy after five days in
those receiving treatment (n¼ 7) compared to sham
stimulation (n¼ 6).42 A case study suggested that
rTMS-based decreases in apathy are paralleled by
increasing interhemispheric connectivity.43 Both studies
utilized small samples, however, necessitating replica-
tions in larger trials.
Discussion
Apathy is a quantitative reduction in GDB and is a
common but under-studied syndrome following
stroke. We provided an overview on apathy in stroke,
highlighting contemporary issues on definitions, diag-
nosis, neurobiology, consequences, and treatments. A
diagnosis of apathy may be complicated by symptoms
of fatigue and especially depression, which may appear
behaviorally similar to apathy. Apathy may be the
result of damage to neural networks underlying
cognitive functions that support motivated GDB.
Post-stroke neurophysiological processes may lead to
structural and functional network changes, leading to
longitudinal changes in apathy. Post-stroke changes to
these networks may explain why some patients show
improving or worsening apathy over time, although
further testing is required.
Finally, apathy is associated with numerous behav-
ioral, cognitive, and emotional concomitants, impact-
ing quality of life and functional outcomes. These
emphasize the importance of treating apathy, but
unfortunately, pharmacological and behavioral inter-
ventions have yielded inconclusive results. Although
some treatments, such as dopamine pharmacotherapy
and rTMS, show promise for treating apathy, no treat-
ment can be fully recommended.
Clinical recognition of post-stroke apathy is import-
ant, as it informs outcomes and treatment approaches.
Patients with apathy may recover functional abilities
more slowly and could be at-risk for future vascular
events, dementia, and mortality, stressing the import-
ance of early detection and continued monitoring.
Little evidence suggests that SSRIs effectively treat
apathy and should only be used in patients with con-
comitant depression. It should be noted, however, that
our non-systematic review may have led to bias, such as
in article inclusion, and further systematic analyses may
be required to assess treatment efficacy.
Research on neurobiological mechanisms of apathy
should consider adopting the network-based framework
for investigating the presentation and development of
apathy. Focal lesions or peripheral degeneration in
brain networks should be examined in conjunction with
different behavioral manifestations of apathy.
Epidemiological and outcome research on apathy could
also benefit from better stroke and apathy subtyping.
Finally, validating apathy measures in stroke patients
would improve study reliability and help characterize spe-
cific motivational deficits in post-stroke patients. These
could then inform approaches for treating apathy, such
as pharmacological interventions to target neurotransmit-
ter systems, behavioral interventions to target cognitive-
behavioral symptoms, and brain stimulation approaches
that target distinct brain networks.
Search strategy and selection criteria
PubMed was searched for articles published in English
between 1 January 1970 and 31 December 31 using the
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following terms: (apath* OR indifferen* OR abuli* OR
motivat*) AND (stroke OR infarct OR cerebrovascu-
lar* OR lacun* OR infarct* OR small vessel disease*
OR white matter hyperintens* OR white matter lesion*
OR white matter disease* OR microbleed* OR ische-
mia OR ischaemia OR haemorrhag* OR hemorrhag*
OR perivascular space* OR leukoaraiosis OR leukoen-
cephalopath* OR age-related white matter damage OR
vascular dementia). This returned 3210 results. Titles
and abstracts were screened by one of the authors
(JT) for relevance to the topics covered in this review.
Full-text articles of relevant articles were retrieved and
reviewed. Reference lists from these articles were
screened for other eligible studies. Further relevant stu-
dies were also taken from the authors’ own published
works.
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